Posted by Staff
Clinical Trials
Thursday, April 18th, 2013
ADA Diabetes Care: April 11, 2013
OBJECTIVE To assess glucose-lowering mechanisms of sitagliptin (S), metformin (M), and the two combined (M+S).
RESEARCH DESIGN AND METHODS We randomized 16 patients with type 2 diabetes mellitus (T2DM) to four 6-week treatments with placebo (P), M, S, and M+S. After each period, subjects received a 6-h meal tolerance test (MTT) with [14C]glucose to calculate glucose kinetics. Read more
Posted by Staff
Clinical Trials
Thursday, April 18th, 2013
ADA Diabetes Care: April 11, 2013
OBJECTIVE The purpose of this study was to determine the efficacy of two internet-based psycho-educational programs designed to improve outcomes for youth with type 1 diabetes transitioning to adolescence.
RESEARCH DESIGN AND METHODS The study was a multisite clinical trial of 320 youth (age 11–14 years; 37% minority; 55% female) randomized to one of two internet-based interventions: TeenCope or Managing Diabetes. Primary outcomes were HbA1c and quality of life (QOL). Read more
Posted by Staff
Clinical Trials
Thursday, April 18th, 2013
European Medicines Agency: April 9, 2013
Almost 62% of the patients in pivotal trials submitted in marketing-authorisation applications (MAAs) to the European Medicines Agency between January 2005 and December 2011 were recruited outside of the European Economic Area (EEA) and Switzerland, according to an analysis performed by the Agency.
The report on clinical trials submitted in MAAs to the European Medicines Agency, published today, provides an overview of the distribution of the numbers of patients, investigator sites and pivotal clinical trials included in MAAs submitted to the Agency, as well as the number and location of sites that were inspected. Read more
Posted by Staff
News
Sunday, April 14th, 2013
FDA: April 8, 2013
- Animas 2020 Insulin Infusion Pumps
Lot numbers: All lots manufactured from March 1, 2012 to November 30, 2012.
Manufacturing and Distribution Dates: The affected products were manufactured from March 1, 2012 to November 30, 2012 and distributed from March 1, 2012 to September 30, 2012.
Use:
The Animas 2020 Insulin Pumps are used to deliver insulin directly into your blood for the treatment of diabetes.
Recalling Firm:
Animas Corporation
200 Lawrence Dr.
West Chester, PA 19380-3428
Reason for Recall:
Animas has identified a component issue affecting Animas(R) 2020 Infusion Insulin
Pumps manufactured from March 1, 2012 to November 30, 2012. The component issue may trigger the pumps to sound a false alarm or warning related to one of the following: Read more
Posted by Staff
News
Sunday, April 14th, 2013
ADA Diabetes Care: April 5, 2013
OBJECTIVE To compare risk of all-cause mortality, cardiovascular disease (CVD) mortality, acute myocardial infarction (AMI) mortality, stroke mortality, and hospitalizations for males and females with and without diabetes and those with diabetes diagnosed early and late.
RESEARCH DESIGN AND METHODS Population-based retrospective cohort study including 73,783 individuals aged 25 years or older in Newfoundland and Labrador, Canada (15,152 with diabetes; 9,517 with late diagnoses). Read more
Posted by Staff
News
Sunday, April 14th, 2013
ADA Diabetes Care: April 5, 2013
OBJECTIVE To compare clinical profile of long-term survivors and nonsurvivors with type 2 diabetes (T2DM).
RESEARCH DESIGN AND METHODS After conducting a retrospective survey of >200,000 case records, we identified T2DM survivors (>40 years of duration) and age at diagnosis and sex-matched T2DM non survivors. Read more
Posted by Staff
News
Sunday, April 14th, 2013
Diabetologia: April 2013
Aims/hypothesis
This study is a 19 year observational follow-up of a pragmatic open multicentre cluster-randomised controlled trial of 6 years of structured personal diabetes care starting from diagnosis.
Methods
A total of 1,381 patients aged ≥40 years and newly diagnosed with type 2 diabetes were followed up in national registries for 19 years. Read more
